Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study
单位：[1]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Guangdong, Peoples R China[2]Shanghai First Peoples Hosp, Canc Ctr, Shanghai, Peoples R China[3]Linyi Tumor Hosp, Dept Med Oncol, Linyi, Peoples R China[4]Peking Univ, Dept Digest Oncol, Canc Hosp, Beijing, Peoples R China[5]Harbin Med Univ, Dept Med Oncol, Affiliated Tumour Hosp, Harbin, Heilongjiang, Peoples R China[6]Wuhan Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[7]Shantou Univ, Dept Med Oncol, Affiliated Tumour Hosp, Med Coll, Shantou, Peoples R China[8]Zhejiang Univ, Dept Med Oncol, Affiliated Hosp 1, Med Coll, Hangzhou, Zhejiang, Peoples R China浙江大学医学院附属第一医院[9]Sichuan Univ, Canc Ctr, West China Hosp, Chengdu, Sichuan, Peoples R China四川大学华西医院[10]Fudan Univ, Tumor Hosp, Shanghai, Peoples R China[11]Fujian Med Univ, Dept Med Oncol, Union Hosp, Fuzhou, Peoples R China[12]Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Henan, Peoples R China河南省肿瘤医院
医学